文献速递胸部肿瘤

布帕利塞联合胸部放疗及其对肿瘤缺氧的影响:晚期非小细胞肺癌患者的I期研究

Buparlisib with thoracic radiotherapy and its effect on tumour hypoxia: A phase I study in patients with advanced non-small cell lung carcinoma.
PubMed 文献 · Eur J Cancer · 2019-04-13

这项I期研究在晚期非小细胞肺癌患者中评估布帕利塞联合胸部放疗的安全性及对肿瘤缺氧的影响。21例患者入组,最大耐受剂量为100 mg,未报告剂量限制性毒性,94%的治疗相关不良事件≤2级;可评估影像的15例中10例(67%)为应答者,最大耐受剂量下缺氧体积中位下降20%。

要点

  • 布帕利塞50、80、100 mg每日一次口服2周,第2周行胸部放疗20 Gy/5次。
  • 未报告剂量限制性毒性,最大耐受剂量为100 mg,扩展期10例接受该剂量。
  • 可评估影像的15例中10例(67%)为应答者,最大耐受剂量下缺氧体积中位下降20%。

核心结论

  • 这是首个在非小细胞肺癌中联合PI3K抑制剂与放疗并研究PI3K抑制对肿瘤缺氧影响的临床试验。
  • 该联合方案耐受良好,PI3K抑制可减少缺氧,需进一步研究该新型放疗增敏剂能否改善放疗结局。

研究设计与样本

  • 采用3+3剂量递增及剂量扩展的I期试验,纳入晚期非小细胞肺癌患者。
  • 布帕利塞剂量水平为50 mg、80 mg、100 mg每日一次口服,连用2周,第2周行姑息性胸部放疗20 Gy分5次。
  • 共入组21例患者,其中9例可评估最大耐受剂量分析。
  • 采用18F-氟米索硝唑正电子发射断层扫描-计算机断层扫描于基线和布帕利塞治疗1周后测量肿瘤缺氧体积。

主要发现

  • 未报告剂量限制性毒性,因此宣布100 mg为最大耐受剂量,扩展期10例患者接受该剂量。
  • 94%的治疗相关不良事件≤2级,按患者计最常见为乏力(67%)、恶心(24%)和食欲下降(19%)。
  • 1例严重不良事件(3级低白蛋白血症)可能与布帕利塞相关。
  • 未报告意外的放疗毒性。
  • 可评估影像分析的15例患者中10例(67%)为应答者,最大耐受剂量下缺氧体积中位下降20%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需进一步研究该新型放疗增敏剂能否改善放疗结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pre-clinically, phosphoinositide 3-kinase (PI3K) inhibition radiosensitises tumours by increasing intrinsic radiosensitivity and by reducing tumour hypoxia. We assessed whether buparlisib, a class 1 PI3K inhibitor, can be safely combined with radiotherapy in patients with non-small cell lung carcinoma (NSCLC) and investigated its effect on tumour hypoxia. METHODS: This was a 3 + 3 dose escalation and dose expansion phase I trial in patients with advanced NSCLC. Buparlisib dose levels were 50 mg, 80 mg and 100 mg once daily orally for 2 weeks, with palliative thoracic radiotherapy (20 Gy in 5 fractions) delivered during week 2. Tumour hypoxic volume (HV) was measured using 18F-fluoromisonidazole positron-emission tomography-computed tomography at baseline and following 1 week of buparlisib. RESULTS: Twenty-one patients were recruited with 9 patients evaluable for maximum tolerated dose (MTD) analysis. No dose-limiting toxicity was reported; therefore, 100 mg was declared the MTD, and 10 patients received this dose in the expansion phase. Ninety-four percent of treatment-related adverse events were ≤grade 2 with fatigue (67%), nausea (24%) and decreased appetite (19%) most common per patient. One serious adverse event (grade 3 hypoalbuminaemia) was possibly related to buparlisib. No unexpected radiotherapy toxicity was reported. Ten (67%) of 15 patients evaluable for imaging analysis were responders with 20% median reduction in HV at the MTD. CONCLUSION: This is the first clinical trial to combine a PI3K inhibitor with radiotherapy in NSCLC and investigate the effects of PI3K inhibition on tumour hypoxia. This combination was well tolerated and PI3K inhibition reduced hypoxia, warranting investigation into whether this novel class of radiosensitisers can improve radiotherapy outcomes.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. McGowan DR, Skwarski M, Bradley KM, et al. Buparlisib with thoracic radiotherapy and its effect on tumour hypoxia: A phase I study in patients with advanced non-small cell lung carcinoma. Eur J Cancer. 2019. PMID: 30991262. doi:10.1016/j.ejca.2019.03.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。